Host–guest complexes of docetaxel, an anti-cancer drug

被引:0
|
作者
T. Lakshmi Kumar
Pooja Guleria
Peddy Vishweshwar
A. Sivalakshmidevi
J. Moses Babu
K. Vyas
Palle V. R. Acharyulu
N. M. Sekhar
B. Selva Kumar
机构
[1] Dr. Reddy’s Laboratories Ltd.,Department of Analytical Research, Discovery Research
[2] Dr. Reddy’s Laboratories Ltd.,Analytical Research and Development, Integrated Product Development
[3] Dr. Reddy’s Laboratories Ltd.,Research & Development, Integrated Product Development
关键词
Anti-cancer drug; Docetaxel; Host–guest complex; Hydrogen bond; Inclusion compound; Supramolecular chemistry;
D O I
暂无
中图分类号
学科分类号
摘要
Host–guest complexes of Docetaxel 1, an anti-cancer drug have been isolated and crystal structures are described. Docetaxel crystallized in the 1:1 molar ratio with n-butanol, dimethylformamide (DMF) and acetonitrile (ACN) during crystallization from the respective solvents. In all the three complexes (1 · n-butanol, 1 · DMF and 1 · ACN), docetaxel formed a host framework through hydrogen bonds and the guest solvent molecules occupied the channels. The host is hydrogen bonded to the guest molecules through hydroxyl moieties. Interestingly, 1 · n-butanol, 1 · DMF and a literature 1 · CH3OH · H2O (1:1:1) host–guest complexes are isomorphs. Further, 1 · ACN complex unit cell parameters are similar (same space group) to the marketed docetaxel trihydrate polymorph (form A).
引用
收藏
页码:261 / 269
页数:8
相关论文
共 50 条
  • [31] CYTEMBENA - ANTI-CANCER DRUG WITH AN UNIQUE STRUCTURE
    VONHOFF, DD
    ROZENCWEIG, M
    MUGGIA, FM
    BIOMEDICINE, 1977, 26 (06): : 388 - 392
  • [32] New anti-cancer photosensitizer drug developed
    Kashyap, Meenakshi
    NATIONAL MEDICAL JOURNAL OF INDIA, 2007, 20 (03): : 161 - 161
  • [33] Atropisomerism transforming anti-cancer drug discovery
    Patel, Simran
    Sandha, Khushi
    Waingankar, Anushka
    Jain, Prachi
    Abhyankar, Arundhati
    CHEMICAL BIOLOGY & DRUG DESIGN, 2023, 101 (01) : 138 - 157
  • [34] Extracellular vesicles and anti-cancer drug resistance
    Mc Namee, Niamh
    O'Driscoll, Lorraine
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2018, 1870 (02): : 123 - 136
  • [35] Computational approaches to anti-cancer drug design
    Taylor, SA
    Feldgus, S
    Shields, GC
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U505 - U506
  • [36] Arsenic sulfide as a potential anti-cancer drug
    Ding, Wenping
    Zhang, Lian
    Kim, Sungkyoung
    Tian, Wei
    Tong, Yingying
    Liu, Jianwen
    Ma, Yong
    Chen, Siyu
    MOLECULAR MEDICINE REPORTS, 2015, 11 (02) : 968 - 974
  • [37] Host-Guest Inclusion System of Luteolin with Polyamine--cyclodextrin: Preparation, Characterisation, Anti-oxidant and Anti-cancer Activity
    Liu, Manshuo
    Liao, Rongqiang
    Zhao, Yulin
    Yang, Bo
    AUSTRALIAN JOURNAL OF CHEMISTRY, 2016, 69 (02) : 174 - 182
  • [38] Pharmacokinetic evaluation of a novel anti-cancer drug
    Donnarumma, F.
    Greilberger, J.
    Matzi, V.
    Lindenmann, J.
    Maier, A.
    Leis, H. -J.
    Wintersteiger, R.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 320 - 320
  • [39] Zeneca and Roche promote anti-cancer drug
    不详
    CHEMISTRY IN BRITAIN, 1998, 34 (10) : 11 - 11
  • [40] Signalling Pathways in Anti-cancer Drug Resistance
    Chen, Chen
    Chen, Jiezhong
    Zhao, Kong-Nan
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3007 - 3008